Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

The Integrated Psychological Treatment for Individuals With Schizophrenia in Correctional and Forensic Psychiatric Settings: An Implementation Study.

Dumont M, Briand C, Leblanc Y, Aubin G, Potvin S, Dumais A.

Int J Offender Ther Comp Criminol. 2020 Jan 15:306624X19899607. doi: 10.1177/0306624X19899607. [Epub ahead of print]

PMID:
31941403
2.

Development and validation of the mental health professional culture inventory.

Rapisarda F, Corbière M, Lesage AD, De Benedictis L, Pelletier JF, Felx A, Leblanc Y, Vallarino M, Miglioretti M.

Epidemiol Psychiatr Sci. 2019 Dec 16;29:e80. doi: 10.1017/S2045796019000787.

PMID:
31839026
3.

A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry.

Leblanc Y, Faid V, Lauber MA, Wang Q, Bihoreau N, Chevreux G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Dec 1;1133:121814. doi: 10.1016/j.jchromb.2019.121814. Epub 2019 Oct 16.

PMID:
31731217
4.

Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions.

Leblanc Y, Berger M, Seifert A, Bihoreau N, Chevreux G.

Protein Sci. 2019 Nov;28(11):1982-1992. doi: 10.1002/pro.3733.

PMID:
31583777
5.

Characterization of Human Serum Albumin isoforms by ion exchange chromatography coupled on-line to native mass spectrometry.

Leblanc Y, Bihoreau N, Chevreux G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 15;1095:87-93. doi: 10.1016/j.jchromb.2018.07.014. Epub 2018 Jul 18.

PMID:
30056268
6.

Middle-up analysis of monoclonal antibodies after combined IgdE and IdeS hinge proteolysis: Investigation of free sulfhydryls.

Faid V, Leblanc Y, Bihoreau N, Chevreux G.

J Pharm Biomed Anal. 2018 Feb 5;149:541-546. doi: 10.1016/j.jpba.2017.11.046. Epub 2017 Nov 21.

7.

Co-ensiling as a new technique for long-term storage of agro-industrial waste with low sugar content prior to anaerobic digestion.

Hillion ML, Moscoviz R, Trably E, Leblanc Y, Bernet N, Torrijos M, Escudié R.

Waste Manag. 2018 Jan;71:147-155. doi: 10.1016/j.wasman.2017.10.024. Epub 2017 Nov 6.

PMID:
29102356
8.

Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits.

Chevreux G, Tilly N, Leblanc Y, Ramon C, Faid V, Martin M, Dhainaut F, Bihoreau N.

Haemophilia. 2017 Jul;23(4):e324-e334. doi: 10.1111/hae.13253. Epub 2017 Jun 8.

PMID:
28594467
9.

Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: Case study after a long-term storage at +5°C.

Leblanc Y, Ramon C, Bihoreau N, Chevreux G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 24;1048:130-139. doi: 10.1016/j.jchromb.2017.02.017. Epub 2017 Feb 20.

10.

Identification of potent, selective KDM5 inhibitors.

Gehling VS, Bellon SF, Harmange JC, LeBlanc Y, Poy F, Odate S, Buker S, Lan F, Arora S, Williamson KE, Sandy P, Cummings RT, Bailey CM, Bergeron L, Mao W, Gustafson A, Liu Y, VanderPorten E, Audia JE, Trojer P, Albrecht BK.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4350-4. doi: 10.1016/j.bmcl.2016.07.026. Epub 2016 Jul 19.

PMID:
27476424
11.

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Taylor AM, Côté A, Hewitt MC, Pastor R, Leblanc Y, Nasveschuk CG, Romero FA, Crawford TD, Cantone N, Jayaram H, Setser J, Murray J, Beresini MH, de Leon Boenig G, Chen Z, Conery AR, Cummings RT, Dakin LA, Flynn EM, Huang OW, Kaufman S, Keller PJ, Kiefer JR, Lai T, Li Y, Liao J, Liu W, Lu H, Pardo E, Tsui V, Wang J, Wang Y, Xu Z, Yan F, Yu D, Zawadzke L, Zhu X, Zhu X, Sims RJ 3rd, Cochran AG, Bellon S, Audia JE, Magnuson S, Albrecht BK.

ACS Med Chem Lett. 2016 Mar 15;7(5):531-6. doi: 10.1021/acsmedchemlett.6b00075. eCollection 2016 May 12.

12.

Glycation of polyclonal IgGs: Effect of sugar excipients during stability studies.

Leblanc Y, Bihoreau N, Jube M, Andre MH, Tellier Z, Chevreux G.

Eur J Pharm Biopharm. 2016 May;102:185-90. doi: 10.1016/j.ejpb.2016.03.016. Epub 2016 Mar 15.

13.

Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.

Taylor AM, Vaswani RG, Gehling VS, Hewitt MC, Leblanc Y, Audia JE, Bellon S, Cummings RT, Côté A, Harmange JC, Jayaram H, Joshi S, Lora JM, Mertz JA, Neiss A, Pardo E, Nasveschuk CG, Poy F, Sandy P, Setser JW, Sims RJ 3rd, Tang Y, Albrecht BK.

ACS Med Chem Lett. 2015 Mar 25;7(2):145-50. doi: 10.1021/ml500411h. eCollection 2016 Feb 11.

14.

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.

Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Côté A, Leblanc Y, Nasveschuk CG, Bellon S, Bergeron L, Campbell R, Cantone N, Cooper MR, Cummings RT, Jayaram H, Joshi S, Mertz JA, Neiss A, Normant E, O'Meara M, Pardo E, Poy F, Sandy P, Supko J, Sims RJ 3rd, Harmange JC, Taylor AM, Audia JE.

J Med Chem. 2016 Feb 25;59(4):1330-9. doi: 10.1021/acs.jmedchem.5b01882. Epub 2016 Feb 4.

PMID:
26815195
15.

Implementation of transitions-of-care services through acute care and outpatient pharmacy collaboration.

Gilmore V, Efird L, Fu D, LeBlanc Y, Nesbit T, Swarthout M.

Am J Health Syst Pharm. 2015 May 1;72(9):737-44. doi: 10.2146/ajhp140504.

PMID:
25873621
16.

Development of methyl isoxazoleazepines as inhibitors of BET.

Hewitt MC, Leblanc Y, Gehling VS, Vaswani RG, Côté A, Nasveschuk CG, Taylor AM, Harmange JC, Audia JE, Pardo E, Cummings R, Joshi S, Sandy P, Mertz JA, Sims RJ 3rd, Bergeron L, Bryant BM, Bellon S, Poy F, Jayaram H, Tang Y, Albrecht BK.

Bioorg Med Chem Lett. 2015 May 1;25(9):1842-8. doi: 10.1016/j.bmcl.2015.03.045. Epub 2015 Mar 24. Erratum in: Bioorg Med Chem Lett. 2015 Sep 1;25(17):3755. Jayaran, Hariharan [corrected to Jayaram, Hariharan].

PMID:
25851940
17.

Collegiate misuse of prescription stimulants: examining differences in self-worth.

Giordano AL, Prosek EA, Reader EA, Bevly CM, Turner KD, LeBlanc YN, Vera RA, Molina CE, Garber SA.

Subst Use Misuse. 2015 Feb;50(3):358-65. doi: 10.3109/10826084.2014.980956. Epub 2014 Dec 4.

PMID:
25474729
18.

Development and implementation of a postdischarge home-based medication management service.

Pherson EC, Shermock KM, Efird LE, Gilmore VT, Nesbit T, LeBlanc Y, Brotman DJ, Deutschendorf A, Swarthout MD.

Am J Health Syst Pharm. 2014 Sep 15;71(18):1576-83. doi: 10.2146/ajhp130764.

PMID:
25174018
19.

A practical synthesis of indoles via a Pd-catalyzed C-N ring formation.

Vaswani RG, Albrecht BK, Audia JE, Côté A, Dakin LA, Duplessis M, Gehling VS, Harmange JC, Hewitt MC, Leblanc Y, Nasveschuk CG, Taylor AM.

Org Lett. 2014 Aug 15;16(16):4114-7. doi: 10.1021/ol5018118. Epub 2014 Jul 28.

PMID:
25068576
20.

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.

Gehling VS, Hewitt MC, Vaswani RG, Leblanc Y, Côté A, Nasveschuk CG, Taylor AM, Harmange JC, Audia JE, Pardo E, Joshi S, Sandy P, Mertz JA, Sims RJ 3rd, Bergeron L, Bryant BM, Bellon S, Poy F, Jayaram H, Sankaranarayanan R, Yellapantula S, Bangalore Srinivasamurthy N, Birudukota S, Albrecht BK.

ACS Med Chem Lett. 2013 Jul 16;4(9):835-40. doi: 10.1021/ml4001485. eCollection 2013 Sep 12.

21.

An evidence-based systematic review of kudzu (Pueraria lobata) by the Natural Standard Research Collaboration.

Ulbricht C, Costa D, Dam C, D'Auria D, Giese N, Isaac R, LeBlanc Y, Rusie E, Weissner W, Windsor RC.

J Diet Suppl. 2015 Mar;12(1):36-104. doi: 10.3109/19390211.2014.904123. Epub 2014 May 21. Review.

PMID:
24848872
22.

LC-MS analysis of polyclonal IgGs using IdeS enzymatic proteolysis for oxidation monitoring.

Leblanc Y, Romanin M, Bihoreau N, Chevreux G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15;961:1-4. doi: 10.1016/j.jchromb.2014.04.053. Epub 2014 May 4.

23.

Comparing approaches to integrating refugee and asylum-seeking healthcare professionals in Canada and the UK.

Leblanc Y, Bourgeault IL, Neiterman E.

Healthc Policy. 2013 Oct;9(Spec Issue):126-38.

24.

An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration.

Ulbricht C, Costa D, Dao J, Isaac R, LeBlanc YC, Rhoades J, Windsor RC.

J Diet Suppl. 2013 Jun;10(2):152-70. doi: 10.3109/19390211.2013.793541. Review.

PMID:
23725528
25.

Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.

Powell DA, Black WC, Bleasby K, Chan CC, Deschenes D, Gagnon M, Gordon R, Guay J, Guiral S, Hafey MJ, Huang Z, Isabel E, Leblanc Y, Styhler A, Xu LJ, Zhang L, Oballa RM.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7281-6. doi: 10.1016/j.bmcl.2011.10.040. Epub 2011 Oct 18.

PMID:
22047692
26.

Pharmacists become an integral part of the patient care team.

LeBlanc YC.

Caring. 2011 Aug;30(8):32-4. No abstract available.

PMID:
21939155
27.

Assessing health literacy to identify patients for pharmacist-provided counseling on high-risk medications.

Brown VT, LeBlanc YC, Efird LE, Nesbit T, Wellman JC, Feldman L.

Am J Health Syst Pharm. 2011 Sep 15;68(18):1692-3. doi: 10.2146/ajhp100692. No abstract available.

PMID:
21880881
28.

New indole amide derivatives as potent CRTH2 receptor antagonists.

Zaghdane H, Boyd M, Colucci J, Simard D, Berthelette C, Leblanc Y, Wang Z, Houle R, Lévesque JF, Molinaro C, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Gallant M.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3471-4. doi: 10.1016/j.bmcl.2011.03.085. Epub 2011 Mar 30.

PMID:
21515053
29.

Chemical noise reduction via mass spectrometry and ion/ion charge inversion: amino acids.

Hassell KM, LeBlanc YC, McLuckey SA.

Anal Chem. 2011 May 1;83(9):3252-5. doi: 10.1021/ac200439k. Epub 2011 Apr 5.

30.

Charge inversion via concurrent cation and anion transfer: application to corticosteroids.

Hassell KM, LeBlanc Y, McLuckey SA.

Rapid Commun Mass Spectrom. 2011 Feb 28;25(4):476-82. doi: 10.1002/rcm.4880.

PMID:
21259355
31.

Azaindoles as potent CRTH2 receptor antagonists.

Simard D, Leblanc Y, Berthelette C, Zaghdane MH, Molinaro C, Wang Z, Gallant M, Lau S, Thao T, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Houle R, Lévesque JF.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):841-5. doi: 10.1016/j.bmcl.2010.11.084. Epub 2010 Nov 21.

PMID:
21185722
32.

Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.

Gallant M, Beaulieu C, Berthelette C, Colucci J, Crackower MA, Dalton C, Denis D, Ducharme Y, Friesen RW, Guay D, Gervais FG, Hamel M, Houle R, Krawczyk CM, Kosjek B, Lau S, Leblanc Y, Lee EE, Levesque JF, Mellon C, Molinaro C, Mullet W, O'Neill GP, O'Shea P, Sawyer N, Sillaots S, Simard D, Slipetz D, Stocco R, Sørensen D, Truong VL, Wong E, Wu J, Zaghdane H, Wang Z.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. doi: 10.1016/j.bmcl.2010.11.015. Epub 2010 Nov 5.

PMID:
21106375
33.

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

Léger S, Black WC, Deschenes D, Dolman S, Falgueyret JP, Gagnon M, Guiral S, Huang Z, Guay J, Leblanc Y, Li CS, Massé F, Oballa R, Zhang L.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502. doi: 10.1016/j.bmcl.2009.11.111. Epub 2009 Nov 26.

PMID:
20004097
34.

Conversion of multiple analyte cation types to a single analyte anion type via ion/ion charge inversion.

Hassell KM, LeBlanc Y, McLuckey SA.

Analyst. 2009 Nov;134(11):2262-6. doi: 10.1039/b914304a. Epub 2009 Sep 14.

PMID:
19838413
35.

Discovery of potent and selective DP1 receptor antagonists in the azaindole series.

Leblanc Y, Roy P, Dufresne C, Lachance N, Wang Z, O'Neill G, Greig G, Denis D, Mathieu MC, Slipetz D, Sawyer N, Tsou N.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2125-8. doi: 10.1016/j.bmcl.2009.03.010. Epub 2009 Mar 9.

PMID:
19307115
36.

Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor.

Han Y, Belley M, Bayly CI, Colucci J, Dufresne C, Giroux A, Lau CK, Leblanc Y, McKay D, Therien M, Wilson MC, Skorey K, Chan CC, Scapin G, Kennedy BP.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3200-5. doi: 10.1016/j.bmcl.2008.04.064. Epub 2008 Apr 29.

PMID:
18477508
37.

Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.

Beaulieu C, Guay D, Wang Z, Leblanc Y, Roy P, Dufresne C, Zamboni R, Berthelette C, Day S, Tsou N, Denis D, Greig G, Mathieu MC, O'Neill G.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2696-700. doi: 10.1016/j.bmcl.2008.03.015. Epub 2008 Mar 10.

PMID:
18359630
38.

Electron transfer dissociation of doubly sodiated glycerophosphocholine lipids.

Liang X, Liu J, LeBlanc Y, Covey T, Ptak AC, Brenna JT, McLuckey SA.

J Am Soc Mass Spectrom. 2007 Oct;18(10):1783-8. Epub 2007 Jul 26.

39.

Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.

Asante-Appiah E, Patel S, Desponts C, Taylor JM, Lau C, Dufresne C, Therien M, Friesen R, Becker JW, Leblanc Y, Kennedy BP, Scapin G.

J Biol Chem. 2006 Mar 24;281(12):8010-5. Epub 2006 Jan 6.

40.

A cost-effectiveness analysis of interactive paediatric telecardiology.

Sicotte C, Lehoux P, Van Doesburg N, Cardinal G, Leblanc Y.

J Telemed Telecare. 2004;10(2):78-83.

PMID:
15068642
41.

The development of potent non-peptidic PTP-1B inhibitors.

Dufresne C, Roy P, Wang Z, Asante-Appiah E, Cromlish W, Boie Y, Forghani F, Desmarais S, Wang Q, Skorey K, Waddleton D, Ramachandran C, Kennedy BP, Xu L, Gordon R, Chan CC, Leblanc Y.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1039-42.

PMID:
15013019
42.

Feasibility and outcome evaluation of a telemedicine application in speech-language pathology.

Sicotte C, Lehoux P, Fortier-Blanc J, Leblanc Y.

J Telemed Telecare. 2003;9(5):253-8.

PMID:
14599327
43.

Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.

Leblanc Y, Roy P, Wang Z, Li CS, Chauret N, Nicoll-Griffith DA, Silva JM, Aubin Y, Yergey JA, Chan CC, Riendeau D, Brideau C, Gordon R, Xu L, Webb J, Visco DM, Prasit P.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3317-20.

PMID:
12392741
44.

The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates.

Asante-Appiah E, Patel S, Dufresne C, Roy P, Wang Q, Patel V, Friesen RW, Ramachandran C, Becker JW, Leblanc Y, Kennedy BP, Scapin G.

Biochemistry. 2002 Jul 23;41(29):9043-51.

PMID:
12119018
45.

Ultra-relativistic electrons in Jupiter's radiation belts.

Bolton SJ, Janssen M, Thorne R, Levin S, Klein M, Gulkis S, Bastian T, Sault R, Elachi C, Hofstadter M, Bunker A, Dulk G, Gudim E, Hamilton G, Johnson WT, Leblanc Y, Liepack O, McLeod R, Roller J, Roth L, West R.

Nature. 2002 Feb 28;415(6875):987-91.

PMID:
11875557
46.

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitor.

Nicoll-Griffith DA, Silva JM, Chauret N, Day S, Leblanc Y, Roy P, Yergey JA, Dixit R, Patrick D.

Drug Metab Dispos. 2001 Feb;29(2):159-65.

PMID:
11159806
47.

SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.

Leblanc Y, Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm E, Guay J, Léger S, Li CS, Riendeau D, Visco D, Wang Z, Webb J, Xu LJ, Prasit P.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2207-12.

PMID:
10465547
48.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
49.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

PMID:
10406640
50.

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.

J Med Chem. 1999 Apr 8;42(7):1274-81.

PMID:
10197970

Supplemental Content

Loading ...
Support Center